This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

The relationship between climate change and infectious disease is raising questions around therapeutic innovation, logistical ...

There are currently no FDA- or EMA-approved treatment options available for any form of frontotemporal dementia.

The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.

The EC has granted approval for presentation of GSK's Menveo vaccine (MenACWY) for invasive meningococcal disease (IMD).

Trump's controversial administration nominees signal global ramifications for drug regulation, health funding and pharmaceutical investment.

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic ...

The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...